These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. Dominguez-Rodriguez A; Abreu-Gonzalez P; Reiter RJ World J Cardiol; 2014 Mar; 6(3):100-6. PubMed ID: 24669291 [TBL] [Abstract][Full Text] [Related]
4. Myocardial infarction: is bepridil, a new calcium antagonist, able to improve the course of the acute phase? Flammang D; Waynberger M; Paillet R; Pruvot C; Cosson G; Chassing A Cardiovasc Drugs Ther; 1989 Jan; 2(6):771-81. PubMed ID: 2488091 [TBL] [Abstract][Full Text] [Related]
5. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Jenkins RR; Del Signore CM; Sauer P; Skelly C Lipids; 1992 Jul; 27(7):539-42. PubMed ID: 1360612 [TBL] [Abstract][Full Text] [Related]
6. According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction? Kjekshus JK Cardiovasc Drugs Ther; 1988 May; 2(1):113-9. PubMed ID: 2908718 [TBL] [Abstract][Full Text] [Related]
7. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. Croft CH; Rude RE; Gustafson N; Stone PH; Poole WK; Roberts R; Strauss HW; Raabe DS; Thomas LJ; Jaffe AS Circulation; 1986 Jun; 73(6):1281-90. PubMed ID: 3009050 [TBL] [Abstract][Full Text] [Related]
8. Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia. Multicentre investigation for the limitation of infarct size (MILIS). Roberts R; Braunwald E; Muller JE; Croft C; Gold HK; Hartwell TD; Jaffe AS; Mullin SM; Parker C; Passamani ER Br Heart J; 1988 Oct; 60(4):290-8. PubMed ID: 3056476 [TBL] [Abstract][Full Text] [Related]
9. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. Roberts R; Croft C; Gold HK; Hartwell TD; Jaffe AS; Muller JE; Mullin SM; Parker C; Passamani ER; Poole WK N Engl J Med; 1984 Jul; 311(4):218-25. PubMed ID: 6377070 [TBL] [Abstract][Full Text] [Related]
10. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Kjekshus JK Am J Cardiol; 1986 Apr; 57(12):43F-49F. PubMed ID: 2871745 [TBL] [Abstract][Full Text] [Related]
11. Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. Shivkumar K; Schultz L; Goldstein S; Gheorghiade M Am Heart J; 1998 Feb; 135(2 Pt 1):261-7. PubMed ID: 9489974 [TBL] [Abstract][Full Text] [Related]
12. Propranolol in acute myocardial infarction: the MILIS experience. Rude RE; Buja LM; Willerson JT Am J Cardiol; 1986 Apr; 57(12):38F-42F. PubMed ID: 2871744 [TBL] [Abstract][Full Text] [Related]
13. Use of beta-adrenergic blocking agents after myocardial infarction. Frishman WH; Ruggio J; Furberg C Postgrad Med; 1985 Dec; 78(8):40-6, 49-53. PubMed ID: 2866506 [TBL] [Abstract][Full Text] [Related]